1. DOP15 Fluorescent labelled vedolizumab for real-time visualization and quantification of local drug distribution and pharmacodynamics in Inflammatory Bowel Diseases during endoscopy. (21st January 2022) Authors: Gabriëls, R Y; Linssen, M; van der Waaij, A; Volkmer, P; Hooghiemstra, W; Kats-Ugurlu, G; Robinson, D; Dijkstra, G; Nagengast, W Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i064 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P812 Fluorescently labelled vedolizumab identified macroscopic and microscopic mucosal drug distribution in patients with inflammatory bowel disease. (30th January 2023) Authors: Van Der Waaij, A; Gabriëls, R; Linssen, M; Volkmer, P; Robinson, D; Hermoso, M; Karrenbeld, A; Festen, E; Dijkstra, G; Kats-Urgulu, G; Nagengast, W Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i944 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗